指南与共识血脂与心血管预防冠心病

非裔美国人他汀治疗指南联合冠脉钙化评估的成本效果

Cost-effectiveness of Contemporary Statin Use Guidelines With or Without Coronary Artery Calcium Assessment in African American Individuals.
指南 / 共识 · JAMA Cardiol · 2020-01-01

该研究采用微观模拟模型,基于杰克逊心脏研究中472名中危非裔美国人数据,评估2013年ACC/AHA指南(不推荐CAC评估)与2018年指南(推荐CAC评估指导他汀)的成本效果。当患者强烈偏好避免每日服药时,2018年CAC策略更具成本效果。

要点

  • 中危非裔美国人中,CAC评估指导他汀策略在患者偏好避免每日服药时更具成本效果。
  • CAC检测可能有助于他汀使用的共享决策。

核心结论

  • CAC评估指导的他汀策略相比所有中危非裔美国人直接起始他汀,可能具有成本效果。
  • 当患者强烈偏好避免每日服药时,CAC策略可能以更低成本提供更大质量调整预期寿命。

研究设计与样本

  • 微观模拟模型,评估终身 horizon 的预期寿命、生活质量、成本和健康结局。
  • 使用杰克逊心脏研究中472名中危非裔美国人数据及已发表美国人群数据。
  • 数据分析时间为2018年11月11日至2019年11月1日。

主要发现

  • 304名接受CAC评估的参与者中178人(58.6%)CAC评分非0。

关键数值与推荐

  • 2013年ACC/AHA指南不推荐CAC评估。
  • 2018年ACC/AHA指南推荐单次CAC评分非0时靶向使用仿制药中等强度他汀。
  • QALY和成本按每年3%贴现。

临床怎么用

  • 对中危非裔美国人,可考虑CAC评估以指导他汀起始决策。
  • 当患者强烈偏好避免每日服药时,CAC评估策略可能更优。
  • CAC检测可用于共享决策。

局限性

  • 模型基于杰克逊心脏研究472名参与者数据,样本量有限。
  • 结果可能受模型假设和输入数据影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Clinical and economic consequences of statin treatment guidelines supplemented by targeted coronary artery calcium (CAC) assessment have not been evaluated in African American individuals, who are at increased risk for atherosclerotic cardiovascular disease and less likely than non-African American individuals to receive statin therapy. OBJECTIVE: To evaluate the cost-effectiveness of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline without a recommendation for CAC assessment vs the 2018 ACC/AHA guideline recommendation for use of a non-0 CAC score measured on one occasion to target generic-formulation, moderate-intensity statin treatment in African American individuals at risk for atherosclerotic cardiovascular disease. DESIGN, SETTING, AND PARTICIPANTS: A microsimulation model was designed to estimate life expectancy, quality of life, costs, and health outcomes over a lifetime horizon. African American-specific data from 472 participants in the Jackson Heart Study (JHS) at intermediate risk for atherosclerotic cardiovascular disease and other US population-specific data on individuals from published sources were used. Data analysis was conducted from November 11, 2018, to November 1, 2019. MAIN OUTCOMES AND MEASURES: Lifetime costs and quality-adjusted life-years (QALYs), discounted at 3% annually. RESULTS: In a model-based economic evaluation informed in part by follow-up data, the analysis was focused on 472 individuals in the JHS at intermediate risk for atherosclerotic cardiovascular disease; mean (SD) age was 63 (6.7) years. The sample included 243 women (51.5%) and 229 men (48.5%). Of these, 178 of 304 participants (58.6%) who underwent CAC assessment had a non-0 CAC score. In the base-case scenario, implementation of 2013 ACC/AHA guidelines without CAC assessment provided a greater quality-adjusted life expectancy (0.0027 QALY) at a higher cost ($428.97) compared with the 2018 ACC/AHA guideline strategy with CAC assessment, yielding an incremental cost-effectiveness ratio of $158 325/QALY, which is considered to represent low-value care by the ACC/AHA definition. The 2018 ACC/AHA guideline strategy with CAC assessment provided greater quality-adjusted life expectancy at a lower cost compared with the 2013 ACC/AHA guidelines without CAC assessment when there was a strong patient preference to avoid use of daily medication therapy. In probability sensitivity analyses, the 2018 ACC/AHA guideline strategy with CAC assessment was cost-effective compared with the 2013 ACC/AHA guidelines without CAC assessment in 76% of simulations at a willingness-to-pay value of $100 000/QALY when there was a preference to lose 2 weeks of perfect health to avoid 1 decade of daily therapy. CONCLUSIONS AND RELEVANCE: A CAC assessment-guided strategy for statin therapy appears to be cost-effective compared with initiating statin therapy in all African American individuals at intermediate risk for atherosclerotic cardiovascular disease and may provide greater quality-adjusted life expectancy at a lower cost than a non-CAC assessment-guided strategy when there is a strong patient preference to avoid the need for daily medication. Coronary artery calcium testing may play a role in shared decision-making regarding statin use.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Spahillari A, Zhu J, Ferket BS, et al. Cost-effectiveness of Contemporary Statin Use Guidelines With or Without Coronary Artery Calcium Assessment in African American Individuals. JAMA Cardiol. 2020. PMID: 32401264. doi:10.1001/jamacardio.2020.1240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。